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M A J O R A R T I C L E
Human Papillomavirus Vaccination in
Tanzanian Schoolgirls: Cluster-Randomized
Trial Comparing 2 Vaccine-Delivery Strategies
Deborah Watson-Jones,1,2 Kathy Baisley,1 Riziki Ponsiano,2 Francesca Lemme,1,2 Pieter Remes,2,3 David Ross,1
Saidi Kapiga,1,2 Philippe Mayaud,1 Silvia de Sanjosé,4,5 Daniel Wight,3 John Changalucha,6 and Richard Hayes1
1London School of Hygiene and Tropical Medicine, London, and 3Medical Research Council Social & Public Health Sciences Unit, Glasgow, United
Kingdom; 2Mwanza Intervention Trials Unit and 6National Institute for Medical Research, Mwanza, Tanzania; and 4Unit of Infections and Cancer,
Cancer Epidemiology Research Programme, IDIBELL, Institut Català d’Oncologia, and 5CIBER Epidemiologia y Salud Publica, Barcelona, Spain
Background. We compared vaccine coverage achieved by 2 different delivery strategies for the quadrivalent
human papillomavirus (HPV) vaccine in Tanzanian schoolgirls.
Methods. In a cluster-randomized trial of HPV vaccination conducted in Tanzania, 134 primary schools were
randomly assigned to class-based (girls enrolled in primary school grade [class] 6) or age-based (girls born in
1998; 67 schools per arm) vaccine delivery. The primary outcome was coverage by dose.
Results. There were 3352 and 2180 eligible girls in schools randomized to class-based and age-based delivery,
respectively. HPV vaccine coverage was 84.7% for dose 1, 81.4% for dose 2, and 76.1% for dose 3. For each dose,
coverage was higher in class-based schools than in age-based schools (dose 1: 86.4% vs 82.0% [P = .30]; dose 2:
83.8% vs 77.8% [P = .05]; and dose 3: 78.7% vs 72.1% [P = .04]). Vaccine-related adverse events were rare. Reasons
for not vaccinating included absenteeism (6.3%) and parent refusal (6.7%). School absenteeism rates prior to
vaccination ranged from 8.1% to 23.5%.
Conclusions. HPV vaccine can be delivered with high coverage in schools in sub-Saharan Africa. Compared
with age-based vaccination, class-based vaccination located more eligible pupils and achieved higher coverage.
HPV vaccination did not increase absenteeism rates in selected schools. Innovative strategies will be needed to
reach out-of-school girls.
Clinical Trials Registration. NCT01173900.
Cervical cancer, caused by human papillomavirus
(HPV) [1, 2], is the leading cause of years of life lost
from cancer in much of the developing world [3]. It is
estimated that Tanzania has one of the highest rates of
cervical cancer globally and the third highest mortality
rate from cervical cancer (325 deaths/1 000 000)
among countries eligible for support from the GAVI
Alliance [4, 5]. Developing country screening pro-
grams are frequently limited or absent, leading to late
presentation of cervical cancer and associated high
mortality rates [6]. However, renewed hope for cervi-
cal cancer control has recently come from prophylactic
HPV vaccines.
The efﬁcacy of these vaccines against persistent HPV-
16 and HPV-18 infection and cervical lesions is highest
in subjects who have not yet acquired these HPV types
[7, 8]. The 2 available HPV vaccines, Gardasil (Merck)
and Cervarix (GlaxoSmithKline Biologicals), have pri-
marily targeted females around 9–18 years of age. In the
developed world, the vaccines are often given as part of
a broader program of other vaccinations or via targeted
school-based programs [9]. However, in sub-Saharan
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Africa, preadolescent school girls are not a group routinely tar-
geted by the Expanded Programme on Immunization (EPI),
and strategies for delivery of the vaccine therefore need to be
explored.
We aimed to compare the coverage achieved by 2 different
HPV vaccination strategies in rural and urban schools in Tan-
zania. Schools were cluster-randomized to receive class-based
delivery, in which vaccine was offered to all girls enrolled in
school class 6 in 2010, or age-based delivery, in which vaccine
was offered to all girls born in 1998. The rationale for compar-
ing these 2 strategies was related to potential challenges in
identifying girls by age across all school classes in a country
where many people do not know their date of birth, and the




This was a phase IV cluster-randomized trial (Clinical Trials
Registration: NCT01173900) of 2 vaccine delivery strategies:
an age-based strategy (targeting girls born in 1998) and a
class-based strategy (targeting girls in school class 6). The trial
was conducted in the city of Mwanza and the neighboring dis-
trict of Misungwi in northwest Tanzania. Sufﬁcient vaccine to
vaccinate 5250 girls was provided from Axios Healthcare
Development.
Preliminary Activities
Overall 242 schools were mapped between March and May
2010 to document the number of girls born in 1998 (age 12
years in 2010) and enrolled in class 6 (median age, 13 years in
2010). Schools were classiﬁed as urban or rural on the basis of
government classiﬁcations.
We aimed to obtain an estimate of the number of potential-
ly eligible girls for vaccination in these schools. However, al-
though most school heads were cooperative, collection of
accurate denominator data was hampered by missing register
books, inconsistent data, reluctance to disrupt classes to cross-
check numbers, and absence of some classes at some schools.
Data on eligible pupils were therefore rechecked on the day of
vaccination. Eligible pupils in schools randomized to the age-
based delivery strategy were deﬁned as girls born in 1998,
whereas eligible pupils in schools randomized to the class-
based strategy were deﬁned as girls enrolled in class 6.
Teachers, parents/guardians, and girls in the target vaccina-
tion group were provided with verbal and written information
about HPV vaccination through school, parent, and commu-
nity meetings, through distributed leaﬂets and posters,
through radio messages, and through community drama
troupes, following qualitative research to identify locally con-
textualized ways of promoting and delivering HPV vaccination
[10]. The project adopted an opt-out consent approach for
parents, whereby parents wishing to opt-out indicated to
teachers or the project team that they did not wish their
daughter to be vaccinated.
The median age at sexual debut in this population is ap-
proximately 16–17 years [11]. Selection of the class and age
for the 2 delivery strategies was made in consultation with the
Ministry of Health and Social Welfare and was agreed on at
stakeholder meetings.
To determine whether HPV vaccination would increase ab-
senteeism at schools on vaccination days, a check of pupil
attendance records across different classes was conducted at
10 randomly selected schools (5 urban government, 3 rural
government, and 2 private) over 25 randomly selected school
days during the 6 months prior to starting vaccination.
Randomization and Masking
In total, 134 schools (60 urban government, 60 rural govern-
ment, and 14 private) were randomly allocated to either the
age- or class-based delivery strategy, stratiﬁed by school type.
The allocation was done by an independent statistician. The
study was not blinded.
Vaccine Administration
Eligible girls were offered 3 doses of the quadrivalent L1 virus-
like particle vaccine (which protects against HPV-6, -11, -16
and -18). Vaccination was performed by one EPI nurse per
school. One or two teachers assisted with paperwork and or-
ganization of pupils.
Vaccination was conducted in 4 school rounds over 12
months; each school was visited on a nominated day. The ﬁrst
dose was offered between August and September 2010 (recipi-
ents are referred to as phase 1 girls). Dose 1 was offered at
round 2 between October and November 2010 for girls who
had previously missed dose 1 (ie, phase 2 girls). The second
dose was offered at round 2 for phase 1 girls and at round 3
( January–March 2011) for phase 2 girls. The third dose was
offered at round 3 for phase 1 girls and at round 4 (May–June
2011) for phase 2 girls. Girls who missed dose 2 or 3 were
offered vaccine at subsequent rounds.
After the school vaccine day, vaccine vials were left at the
health facility for 2–4 weeks only, because of cold-storage limita-
tions. A teacher was asked to encourage pupils who had missed
their vaccine dose to attend the nominated health facility.
Vaccinees were instructed to request their parents to call the
team in the event of any suspected adverse event (AE) and to
go to the nearest health facility. Adverse events were also
recorded at each school visit, using adapted national EPI forms.
Serious AEs (SAEs) or AEs that indicated potential vaccine
reactions were investigated by a senior clinician and were
reported to Merck.
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Statistical Considerations
Data were double-entered in OpenClinica 3.0.1 (2009; Akaza
Research; Waltham, MA) and analyzed using Stata 11.0 (Stata-
Corp; College Station, TX).
The sample size was based on methods designed for cluster-
randomized trials and assumed that 120 schools (60 urban
and 60 rural) would be randomized to the 2 delivery strategies,
with an average of 40–45 girls per school, and that the coefﬁ-
cient of variation (k) between clusters (schools) was 0.25.
With an expected sample size of 5000 girls eligible for vacci-
nation, the study had at least 80% power to detect an increase
in vaccination uptake from 65% to 75%, or from 70% to 85%,
between age-based and class-based strategies. Within each
stratum (urban and rural), we had at least 80% power to
Figure 1. Study design and participant enrollment. aIncludes the 25 girls in 3 schools that refused whose eligibility could not be reassessed on the
day of vaccination. b“Intervention” is deﬁned as the provision of human papillomavirus (HPV) vaccine through 2 different school-based strategies.
cBecause the outcome is deﬁned as the receipt of 1, 2, or 3 doses of vaccine by eligible girls, the outcome is known for all eligible girls. Therefore,
there is no loss to follow-up in the sense of the outcome being unknown. dSecondary analysis included all schools that were randomized.
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detect an increase in vaccination uptake from 60% to 75%, or
from 65% to 80%, between the 2 delivery strategies. In addi-
tion, we randomly allocated 7 private schools to each strategy,
irrespective of location (urban or rural,) to obtain meaningful
information about vaccine delivery in private schools. This
number did not provide power to formally test the difference
between strategies in private schools.
Vaccine coverage was calculated for each dose by phase and
vaccination site and by delivery strategy and type of school.
We examined the impact of delivery strategy on vaccine
uptake, using random-effects logistic regression to account for
the correlation within schools. Odds ratios (ORs) and 95%
conﬁdence intervals (CIs) were estimated for the effect of de-
livery strategy in all strata combined and within rural and
urban government schools separately. In addition, we exam-
ined the effect of age on vaccine uptake within the class-based
delivery strategy and of class within the age-based strategy,
using conditional logistic regression to account for correlation
within schools.
Reasons for failing to receive dose 1 were compared
between delivery strategies, using the Pearson χ2 statistic with
the second-order correction of Rao and Scott to account for
the clustered design.
Ethical approval was obtained from the ethics committees
of the Tanzanian Medical Research Coordinating Committee
and the London School of Hygiene and Tropical Medicine.
RESULTS
Mapping of Schools and Numbers of Eligible Pupils
In total, 67 schools were selected for age-based vaccination, and
67 were selected for class-based vaccination; there were 7
private schools, 30 urban government and 30 rural government
schools per arm (Figure 1). Rechecking numbers of pupils on
the day of vaccination found 2180 eligible girls (born in 1998)
in the age-based schools, compared with 1931 in the mapping
data, and 3352 eligible girls (enrolled in class 6) in class-based
schools, compared with 3227 in the mapping data.
Head teachers at 3 private schools randomized to the age-
based strategy, with an estimated 25 eligible pupils in total,
would not permit vaccination, fearing negative parental feed-
back. The pupils in these schools could not be rechecked for
eligibility and were excluded from the denominator. A sensi-
tivity analysis was performed to examine the impact of vacci-
nation strategy on coverage when these schools were included.
Vaccine Coverage
Results are presented for the ﬁrst 12 months of the project. In
total 5532 girls were eligible for vaccination in 64 age-based
schools and 67 class-based schools.
Vaccine coverage for dose 1 was 84.7%, 81.4% of eligible
girls received at least 2 doses of vaccine, and 76.1% received
all 3 doses (Table 1 and Figure 2). Overall, 4503 of 4684 girls
(96.1%) who received dose 1 received dose 2, and 93.5% of
girls who received dose 2 went on to receive dose 3. Dose 1
vaccine coverage was higher in rural government schools
(88.2%) than in urban government schools (82.0%) or private
schools (82.0%). When the 3 private schools that did not par-
ticipate were included, overall coverage for each of the 3 doses
was 84.3%, 81.0%, and 75.8%, respectively.
Only 4.1% of eligible girls received dose 1 or dose 2 at a
health facility; this proportion was even lower for dose 3
(2.1%). By providing another opportunity for girls who
missed dose 1 in the ﬁrst round to be vaccinated in the second
round, another 526 girls (9.7%) received dose 1 (Table 1).
There were 2180 and 3352 eligible girls in the age-based
and class-based vaccination schools, respectively (Table 2).
Vaccine coverage for dose 1 was nonsigniﬁcantly higher with
the class-based strategy, compared with the age-based delivery
strategy (86.4% vs 82.0%; school-type-adjusted OR [AOR],
1.22; 95% CI, .84–1.78; P = .30). Class-based schools had sig-
niﬁcantly better coverage than age-based schools for both dose
2 (83.8% vs 77.8%; AOR, 1.37; 95% CI, .99–1.90; P = .05) and
dose 3 (78.7% vs 72.1%; AOR, 1.36; 95% CI, 1.02–1.82;
Table 1. Coverage for Each Dose Among Eligible Girls, by








Schools (phase 1) 5532 3945 (71.3)
Health facilities (phase 1) 5532 203 (3.7)
Schools (phase 2) 5532 514 (9.3)
Health facilities (phase 2) 5532 22 (0.4)
Total vaccinated with dose 1 5532 4684 (84.7)
Dose 2
Schools (phase 1) 5532 3623 (65.5)
Health facilities (phase 1) 5532 192 (3.5)
Schools (phase 2) 5532 654 (11.8)
Health facilities (phase 2) 5532 34 (0.6)
Total vaccinated with dose 2 5532 4503 (81.4)
Total vaccinated with dose 1
who received dose 2
4684 4503 (96.1)
Dose 3
Schools (phase 1) 5532 3486 (63.0)
Health facilities (phase 1) 5532 102 (1.8)
Schools (phase 2) 5532 608 (11.0)
Health facilities (phase 2) 5532 15 (0.3)
Total vaccinated with dose 3 5532 4211 (76.1)
Total vaccinated with dose 2
who received dose 3
4503 4211 (93.5)
aPhase 1 girls received dose 1 between August and September 2010; phase
2 girls received dose 1 between October and November 2010.
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P = .04). When the 3 private schools that refused to participate
were included, the difference in coverage between the class-
based and age-based strategies was even greater (dose 1: 86.4%
vs 81.1% [AOR, 1.39; 95% CI, .93–2.09; P = .11]; dose 2: 83.8%
vs 76.9% [AOR, 1.52; 95% CI, 1.08–2.15; P = .02]; and dose 3:
78.7% vs 71.3% [AOR, 1.48; 95% CI, 1.09–2.02; P = .01]).
The highest coverage was achieved in rural government
schools that were allocated to the class-based delivery strategy:
89.4% for dose 1, 87.3% for dose 2, and 82.5% for dose 3
(Table 2). Private schools had better coverage with the age-
based strategy than with the class-based strategy when the 3
schools that refused to participate were excluded. However,
when these 3 private schools were included in the analysis,
age-based private schools had the lowest coverage achieved for
each dose (73.3%, 67.8%, and 61.4%, for dose 1, 2, and 3,
respectively).
Within the class-based schools, there was no evidence of a dif-
ference by age in vaccine coverage for dose 1 (P = .34; Table 3),
although there was some evidence that coverage for dose 3
varied by age (P = .06) and was lower in the older age groups
(eg, OR, 1.78 [95% CI, 1.06–3.00] in comparison of coverage for
girls aged ≤12 years to coverage for females aged ≥17 years).
Within the age-based schools, vaccine coverage for each
dose was signiﬁcantly lower for girls in class 7 compared with
girls in class ≤4 (for dose 1, 66.7 vs 85.1%; OR, 0.47; 95% CI,
.26–.87; Table 3).
Reasons for Missing Dose 1
Overall, 848 girls (15.3%) did not receive dose 1. Parent
refusal (6.7%) and absence from school on the day of
vaccination (6.3%) were the main reasons for failure to receive
dose 1 (Table 4). Reasons differed signiﬁcantly by school type
(P < .001). Parent refusal was the major reason for not vacci-
nating in private schools and urban government schools
(95.2% and 52.9% of vaccine nonrecipients, respectively),
whereas absence from school (59.2%) was the main reason in
rural government schools.
The check of pupil attendance records prior to the start of
vaccination found that the proportion of pupils absent on any
one day ranged from 9.6% to 19.7% for class 6 pupils and
from 8.1% to 23.5% for all pupils in classes 4–7 (data not
shown). The 2 private schools in this exercise had lower ab-
senteeism rates for the 4 classes (8.1%–10.9%), compared with
10.0%–19.7% for the urban government schools and 17.6%–
23.5% for the rural government schools. Absence from school
as a documented reason for not receiving a vaccine dose was
not higher on vaccination days, compared with absenteeism
rates prior to vaccination.
Estimated Population Vaccine Coverage
On the basis of 2010 Tanzanian Demographic and Health
Survey data, we estimate that 88%–89% of girls aged 10–12
years are still in school and that the proportion of all girls
who ever attend class 6 is 75%–80% (85%–90% of those in
school at the age of 12 years). Thus, our estimated population
coverage for dose 1 with the standard 6-based approach would
be 65%–70%. If the class-based approach was targeted at lower
standards (eg, standard 4, which an estimated 85% of all girls
would be expect to reach), then estimated coverage would be
>70%, assuming uptake was similar to that in standard 6 [12].
Figure 2. Coverage for dose 3 in each school, by school type and delivery strategy. Abbreviation: Govt, government.
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AE Reports
Overall, 13 398 doses of vaccine were given. There were 11
AEs reported, including 3 SAEs. A generalized rash in a
12-year-old girl 24 hours after dose 1 was the only AE consid-
ered to be related to vaccination. This resolved over 1 week,
and the subject was not given further doses of vaccine. There
were 2 deaths. One death involved a 14-year-old girl 2 weeks
after vaccination and was related to complications of paralytic
ileus, and the other involved a 15-year-old girl 1 month after
vaccination and was probably related to long-standing renal
and cardiac disease. There were 3 episodes of proven or pre-
sumptive malaria, one of which resulted in hospital admission;
4 reports of headache and 1 report of fatigue after vaccination;
and 1 presumptive chest infection.
DISCUSSION
This is the ﬁrst randomized trial to evaluate alternative deliv-
ery strategies for HPV vaccination. Although there is no effec-
tive widespread targeting of younger primary school girls for
vaccination programs in Tanzania, our results show that HPV
vaccination is acceptable, is safe, and can be delivered with
high coverage in a resource-poor setting.
Our results are comparable with those from a larger dem-
onstration project in Uganda and with HPV vaccination pro-
grams in a number of developed countries [13–16]. The 2
studies from Uganda and Tanzania have achieved better cover-
age than programs in countries such as the United States,
Denmark, and the Netherlands, which rely on health center
visits, on-demand vaccination, or private sector provision
[17–21]. A demonstration project in 2 districts in Uganda had
coverage for all 3 doses of 86.3%–87.8% for its school-based
delivery strategy [14]. Uganda has a long established and well-
accepted program of child health interventions through its
Child Days Plus activities, including tetanus toxoid immuniza-
tion in school girls, delivered 2 months per annum [22, 23].
Such well-established programs are not present in many other
sub-Saharan African countries, including Tanzania. Although
there was a program to deliver tetanus toxoid vaccination to
class 7 schoolgirls in Tanzania, this met with challenges in im-
plementation and has recently been discontinued. In addition,
public suspicion about vaccination programs arose in the mid-
2000s after some pupils had adverse reactions to praziquantel
Table 2. Vaccine Coverage by Dose, Type of School, and Delivery Strategy
Dose, School Type
Proportion (%) Vaccinated,a by Strategy
ICC Odds Ratio (95% CI) PAge Based Class Based Overall
Dose 1
Government
Urban 822/1065 (77.2) 1504/1773 (84.8) 2326/2838 (82.0) 0.19 1.52 (.91–2.56) .11
Rural 859/994 (86.4) 1276/1428 (89.4) 2135/2422 (88.2) 0.13 1.11 (.70–1.77) .66
All government 1681/2059 (81.6) 2780/3201 (86.9) 4461/5260 (84.8)
Private 107/121 (88.4) 116/151 (76.8) 223/272 (82.0) …b
All schools 1788/2180 (82.0) 2896/3352 (86.4) 4684/5532 (84.7) 0.21 1.22 (.84–1.78)c .30
Dose 2
Government
Urban 765/1065 (71.8) 1449/1773 (81.7) 2214/2838 (78.0) 0.14 1.80 (1.17–2.76) .008
Rural 831/994 (83.6) 1247/1428 (87.3) 2078/2422 (85.8) 0.12 1.12 (.72–1.73) .61
All government 1596/2059 (77.5) 2696/3201 (84.2) 4292/5260 (81.6)
Private 99/121 (81.8) 112/151 (74.1) 211/272 (77.6) …b
All schools 1695/2180 (77.8) 2808/3352 (83.8) 4503/5532 (81.4) 0.16 1.37 (.99–1.90)c .05
Dose 3
Government
Urban 705/1065 (66.2) 1354/1773 (76.4) 2059/2838 (72.6) 0.11 1.72 (1.17–2.52) .006
Rural 777/994 (78.2) 1178/1428 (82.5) 1955/2422 (80.7) 0.11 1.11 (.74–1.67) .62
All government 1482/2059 (72.0) 2532/3201 (79.1) 4014/5260 (76.3)
Private 90/121 (74.4) 107/151 (70.9) 197/272 (72.4) …b
All schools 1572/2180 (72.1) 2639/3352 (78.7) 4211/5532 (76.1) 0.13 1.36 (1.02–1.82)c .04
Abbreviations: CI, confidence interval; ICC, intracluster correlation coefficient.
a Data are no. of girls eligible/no. vaccinated (%).
b Study was not designed to look at the effect of the strategy in private schools separately.
c Adjusted for school type (private, government urban, and rural).
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as part of a deworming campaign [24]. Despite this, through a
relatively limited sensitization process, we demonstrated that
HPV vaccination was acceptable, and most parents at the se-
lected schools were willing to have their daughters vaccinated.
These results are extremely encouraging for cervical cancer
control program initiatives in sub-Saharan Africa. At the
country level, this study has been extremely valuable for plan-
ning a national HPV immunization program. HPV vaccination
is planned to be added to the national immunization program
in Tanzania in 2012. Vaccine roll out is planned to take place
incrementally through primary school provision, since this
strategy has the best chance of achieving high coverage
because, with the government’s universal primary education
policy, >70% of children attend primary school [25, 26].
In our setting, the class-based vaccination strategy had
higher coverage and achieved vaccination of more pupils,
compared with the age-based strategy. An integrated costing
study has shown that this strategy was also less expensive per
girl vaccinated ($52 and $67 per fully vaccinated girl in urban
and rural schools, respectively), compared with the age-based
Table 3. Findings of Logistic Regression Analysis to Examine the Effect of Class on Vaccine Uptake Within the Age-Based Strategy
and of Age on Vaccine Uptake Within the Class-Based Delivery Strategy
Strategy
Dose 1 Dose 2 Dose 3
Proportion (%)a
Odds Ratio
(95% CI) P Proportion (%)a
Odds Ratio




Class < .001 < .001 < .001
≤4 326/383 (85.1) 1 319/383 (83.3) 1 293/383 (76.5) 1
5 571/688 (83.0) 1.23 (.83–1.85) 558/688 (81.1) 1.18 (.81–1.73) 522/688 (75.9) 1.35 (.96–1.90)
6 819/1000 (81.9) 1.55 (1.02–2.34) 790/1000 (79.0) 1.37 (.93–2.02) 742/1000 (74.2) 1.57 (1.10–2.22)
7 72/108 (66.7) 0.47 (.26–.87) 28/108 (25.9) 0.08 (.04–.15) 15/108 (13.9) 0.06 (.03–.12)
Class based
Age (years) .34 .09 .06
≤12 181/211 (85.8) 1.57 (.84–2.94) 175/211 (82.9) 1.52 (.85–2.71) 167/211 (79.2) 1.78 (1.06–3.00)
13 845/986 (85.7) 1.33 (.81–2.17) 829/986 (84.1) 1.44 (.91–2.28) 778/986 (78.9) 1.58 (1.06–2.37)
14 805/924 (87.1) 1.32 (.82–2.14) 779/924 (84.3) 1.26 (.81–1.97) 740/924 (80.1) 1.56 (1.05–2.32)
15 558/618 (90.3) 1.68 (1.01–2.79) 543/618 (87.9) 1.63 (1.02–2.60) 511/618 (82.7) 1.73 (1.14–2.61)
16 293/340 (86.2) 1.14 (.67–1.93) 277/340 (81.5) 0.97 (.60–1.57) 259/340 (76.2) 1.15 (.75–1.76)
≥17 186/215 (86.5) 1 180/215 (83.7) 1 163/215 (75.8) 1
Analysis by conditional logistic regression, conditioning on school.
Abbreviation: CI, confidence interval.
a Data are no. of girls eligible/no. vaccinated (%).
Table 4. Reasons for Not Receiving Dose 1, by Type of School
Variable Private (n = 272)
Government
Total (n = 5532)Urban (n = 2838) Rural (n = 2422) Any (n = 5260)
Vaccinated 223 (82.0) 2326 (82.0) 2135 (88.2) 4461 (84.8) 4684 (84.7)
Reasons why not vaccinateda
Absent from school 0 181 (6.4) 170 (7.0) 351 (6.7) 351 (6.3)
Sick 0 2 (0.1) 2 (0.1) 4 (0.1) 4 (0.1)
Left the school 2 (0.7) 33 (1.2) 46 (1.9) 79 (1.5) 81 (1.5)
Parent refused 45 (16.5) 265 (9.3) 59 (2.4) 324 (6.2) 369 (6.7)
Pupil refused/ran away 2 (0.7) 6 (0.2) 4 (0.2) 10 (0.2) 12 (0.2)
Pregnant/suspected pregnant 0 0 1 (<0.1) 1 (<0.1) 1 (<0.1)
Allergic to vaccine 0 0 0 0 0
Other 0 22 (0.8) 5 (0.2) 27 (0.5) 27 (0.5)
Missing information 0 3 (0.1) 0 3 (0.1) 3 (<0.1)
Data are no. (%) of girls.
a Reason given at the last school visit by girls who were not vaccinated. Only 1 reason was recorded for each girl.
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strategy ($87 and $98, respectively) [27]. Class-based delivery
has several potential logistical advantages: it may be easier to
liaise with parents and teachers of one speciﬁc class at a
school, only one class is disrupted while vaccination is under-
way, and it is easier to locate pupils in one class. In this region
of Tanzania, class-based delivery allowed us to vaccinate a
larger number of girls than the number vaccinated during
age-based delivery, not just because of better vaccine coverage
but because we found substantially more girls in class 6 than
girls of a single year of age in the same schools [28]. This may
reﬂect the complexity of obtaining reliable listings of girls in a
given age group when they are spread over many different
classes and the relatively wide age range of girls enrolled in
primary school. Disadvantages of class-based delivery include
the fact that some older girls may already have become sexu-
ally active. Although the risk of acquiring HPV-16 and HPV-
18 is greatest during the ﬁrst few years of sexual activity, few
girls are likely to have acquired both HPV-16 and HPV-18 by
the time of vaccination and thus will still gain some beneﬁt
from the HPV vaccine [29]. However, the greatest effect will
be obtained in sexually naive girls, and so the timing of vacci-
nation is important. Lower vaccine coverage in older girls and
those in higher classes, especially for dose 3, is likely to result
from girls leaving primary school during vaccination, and this
is an important consideration when selecting the appropriate
national vaccination strategy.
Because of EPI capacity constraints, we were unable to prag-
matically evaluate coverage through an EPI-delivery system.
However, every effort was made to work with EPI staff for
vaccine delivery and to mimic EPI systems.
As noted above, school-based vaccine delivery will fail to
reach the 20% of girls who are not enrolled in schools and
who may be especially vulnerable to acquiring HPV infection
and cervical cancer. This project was not designed to deliver
vaccine to out-of-school girls, and separate initiatives will
need to be explored to reach this target population in sub-
Saharan Africa.
We observed a higher rate of parent refusal in private
schools. Some head teachers were reluctant to hold speciﬁc
parent-teacher meetings. Teachers at 3 private schools were
concerned about losing income from parents who might dis-
approve or be suspicious of activities not directly related to
education of their children. Liaison with private schools, espe-
cially boarding schools, will need to be speciﬁcally addressed
by any national HPV vaccination program. A national cam-
paign of information about cervical cancer and the beneﬁts of
HPV vaccination may assist in this.
Although absenteeism from schools was the primary reason
for not receiving dose 1 of the HPV vaccine in government
schools, the proportion of pupils absent from school on the
day of vaccination was lower than school records suggested for
the previous 6 months prior to starting vaccination. There was
no evidence that the presence of the vaccine team substantially
increased absenteeism rates at the schools.
Attention will need to be paid to determining denominators
to calculate vaccine coverage. Although the Ministry of Educa-
tion & Vocational Training does collect data on the number of
girls in school by age and class, more timely reporting of
school statistics and checking of school class records at the
time of vaccination will assist in obtaining more accurate data
on vaccine coverage of eligible pupils.
In conclusion, HPV vaccination can be delivered with high
coverage in sub-Saharan Africa. Class-based delivery gave
higher coverage and access to more eligible girls than age-
based delivery in our setting. Other countries may ﬁnd speciﬁc
studies to determine the best delivery strategy to use to be
helpful prior to starting a national HPV vaccination program.
Guidelines for the provision of HPV vaccination in Tanzania
in schools are now being developed in preparation for a na-
tional vaccination program that is schedule to commence in
2012. Speciﬁc strategies will be needed to reach out-of-school
girls for vaccination.
Notes
Acknowledgments. We thank Dafrossa Lyimo, Twalib Ngoma, Sele-
phina Soteli, Ramadhan Hashim, Stephen Makandilo, the HPV mapping
and vaccine teams at NIMR/MITU, and participating EPI nurses and
teachers in Tanzania. We are grateful to Jacqueline Jackson at MITU and
to Tamara Hurst and Eleanor Martins at LSHTM for administrative
support. HPV vaccine was donated from Axios Healthcare Development
through the GARDASIL Access Program.
Disclaimer. The funding agencies had no involvement in the design,
data collection, analysis or interpretation of the results.
Financial support. This work was supported by the Wellcome Trust
(grant WT090318MA), a Cervical Cancer Initiative grant from the Union
of International Cancer Control, and the World Health Organization.
Potential conﬂicts of interest. D.W.-J., P.M., and S.d.S. have received
grant support through their institutions from GlaxoSmithKline Biologicals.
S.d.S. has also received grants from Merck. All other authors report no
potential conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. Koutsky L. Epidemiology of genital human papillomavirus infection.
Am J Med 1997; 102:3–8.
2. Walbloomers JM, Jacobs MV, Manos MM, et al. Human papillomavi-
rus is a necessary cause of invasive cervical cancer worldwide. J Pathol
1999; 189:12–9.
3. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer
as a priority for prevention in different world regions: an evaluation
using years of life lost. Int J Cancer 2004; 109:418–24.
4. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer
2010; 127:2893–917.
5. GAVI Alliance. GAVI investment strategy. Human papillomavirus
analysis, 2008 http://www.gavialliance.org/search/?SearchFor=0&
SearchText=Landscape+analysis+HPV. Accessed 3 February 2012.
HPV Vaccine Delivery Trial in Tanzania • JID 2012:206 (1 September) • 685
6. Sankaranarayanan R, Black RJ, Parkin DM. Cancer survival in devel-
oping countries. IARC Scientiﬁc Publications no. 145. Lyon: Interna-
tional Agency for Research on Cancer, 1998.
7. Paavonen J, Naud P, Salmeron J, et al. Efﬁcacy of human papillomavi-
rus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection
and precancer caused by oncogenic HPV types (PATRICIA): ﬁnal
analysis of a double-blind, randomized study in young women. Lancet
2009; 374:301–14.
8. Future I/II Study Group; Dillner J, Kjaer SK, et al. Four year efﬁcacy
of prophylactic human papillomavirus quadrivalent vaccine against
low grade cervical, vulvar, and vaginal intraepithelial neoplasia
and anogenital warts: randomized controlled trial. BMJ 2010; 341:
c3493.
9. Reeve C, De La Rue S, Pashen D, Culpan M, Chefﬁns T. School-based
vaccinations delivered by general practice in rural north Queensland:
an evaluation of a new human papilloma virus vaccination program.
Commun Dis Intell 2008; 32:94–8.
10. Remes P, Selestine V, Soteli S, et al. Is HPV vaccination in primary
schools acceptable in Tanzanian communities [abstract O-09.07]. In:
Program and abstracts of the 27th International Human Papillomavi-
rus Conference, Berlin, Germany, 17–22 September 2011.
11. Zaba B, Isingo R, Wringe A, Marston M, Slaymaker E, Urassa M. In-
ﬂuence of timing of sexual debut and ﬁrst marriage on sexual behav-
iour in later life: ﬁndings from four survey rounds in the Kisesa
cohort in northern Tanzania. Sex Transm Infect 2009; 85(Suppl 1):
i20–6.
12. Tanzania Demographic and Health Survey 2010. National Bureau of
Statistics, Dar es Salaam. April 2011. http://www.measuredhs.com/
pubs/pdf/FR243/FR243[24June2011].pdf. Accessed 3 February 2012.
13. PATH. Child Health and Development Centre (CHDC), and the
Uganda National Expanded Program on Immunization (UNEPI).
HPV vaccination in Africa: lessons learned from a pilot program in
Uganda. Seattle: PATH, 2011. http://www.rho.org/ﬁles/PATH_HPV_
lessons_learned_Uganda_2011.pdf. Accessed 14 December 2011.
14. LaMontagne DS, Jacob M, Ramos I, Mugisha E, Le NT. Delivery strat-
egies for human papillomavirus vaccinations that achieve high cover-
age in developing countries [abstract P-712]. In: Program and
abstracts of the 26th International Papillomavirus Conference, Mon-
treal, Canada, 3–8 July 2010.
15. Department of Health & Health Protection Agency. Annual HPV
vaccine coverage in England in 2009/2010. http://www.dh.gov.uk/
prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/
dh_123826.pdf. Accessed 14 December 2011.
16. LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine
delivery strategies that achieved high coverage in low- and middle-
income countries. Bull World Health Organ 2011; 89:821–30B.
17. Stokley S, Cohn A, Jain N, McCauley MM. Compliance with recom-
mendations and opportunities for vaccination at ages 11 to 12 years:
evaluation of the 2009 national immunization survey-teen. Arch
Pediatr Adolesc Med 2011; 165:813–8.
18. National and state vaccination coverage among adolescents aged 13
through 17 years—United States, 2010. MMWR Morb Mortal Wkly
Rep 2011; 60:1117–23.
19. European Cervical Cancer Association. HPV vaccination across Europe.
http://www.ecca.info/ﬁleadmin/user_upload/HPV_Vaccination/ECCA_
HPV_Vaccination_April_2009.pdf. Accessed 14 December 2011.
20. Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD. Reasons
for non-vaccination against HPV and future vaccination intentions
among 19–26 year-old women. BMC Womens Health 2010; 10:27.
21. Dorleans F, Giambi C, Dematte L, et al. The current state of introduc-
tion of human papillomavirus vaccination into national immunisation
schedules in Europe: ﬁrst results of the VENICE2 2010 survey. Euro
Surveill 2010; 15:pii = 19730. http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=19730. Accessed 14 December 2011.
22. Seruyange R. Child Days Plus—the Uganda experience. Paper present-
ed at: Introduction of new vaccines—Experience Exchange Meeting,
Pretoria, 28–30 July 2010.
23. Mugyenyi P, Mbabazi W, Kabwongera E. Child Days Plus in Uganda:
best practices and challenges. Paper presented at: Global Immuniza-
tion Meeting, New York, 17–19 February 2009. http://www.who.int/
immunization/newsroom/190209_P_Mugyenyi.pdf. Accessed 12 No-
vember 2011.
24. Mwandoloma H. Vaccination campaign ends amid reservations. The
Guardian. 2 September 2008.
25. Basic statistics in education: 1994–1998. Ministry of Education and
Culture, Dar es Salaam: United Republic of Tanzania, 1999.
26. UNICEF. Tanzania, United Republic of: statistics. http://www.unicef.
org/infobycountry/tanzania_statistics.html. Accessed 2 February 2012.
27. Quentin W, Watson-Jones D, Changalucha J, et al. Costs of delivering
HPV vaccine to school girls in Tanzania [abstract O 05.05]. Paper
presented at: 27th International Papillomavirus Conference, Berlin,
17–22 September 2011. In: Program and abstracts of the 27th Inter-
national Papillomavirus Conference (Berlin), Germany, 2011, 17–22
September.
28. Basic Education Statistics in Tanzania (BEST). 2010 Regional Data.
Ministry of Education and Vocational Training, Dar es Salaam,
United Republic of Tanzania, December, 2010. http://216.15.191.173/
statistics.html. Accessed 3 February 2012.
29. Watson-Jones D, Brown J, De Sanjosé S, et al. Cervical HPV preva-
lence and genotypes in Tanzanian girls and women [abstract P-02.24].
In: Program and abstracts of the 27th International Papillomavirus
Conference, Berlin, Germany, 17–22 September 2011.
686 • JID 2012:206 (1 September) • Watson-Jones et al
